Book traces Sackler OxyContin marketing and limited personal liability

1

Valium built the playbook

The tactics later used on OxyContin were perfected by Arthur Sackler decades earlier while turning Valium into America’s best-selling drug.

Arthur trained as a psychiatrist but made his real money running the medical ad agency William Douglas McAdams for clients including Hoffmann-La Roche. In the 1960s he built the campaigns that made ordinary anxiety look like a condition needing a pill.

The system went far beyond ads. It included manufacturer-funded journals, doctor-to-doctor detailing, paid consultants flown to conferences, and research that sometimes appeared ghostwritten in respected outlets. Sackler called it education; it was built to be indistinguishable from persuasion.

When Purdue later marketed OxyContin it did not invent a new method. It applied Arthur’s already-proven template to a far more dangerous molecule. The family’s later claim that OxyContin’s promotion was unprecedented erases that longer institutional memory.

In practice: Physicians who praised Valium were paid as consultants and flown to symposia that looked independent while being shaped by the manufacturer.

2

Private ownership, split blame

Keeping Purdue private and finances opaque let one Sackler branch profit from OxyContin while another later claimed moral distance.

The three brothers grew up in working-class Brooklyn, trained in medicine, and built a joint fortune, but Purdue Frederick stayed unlisted. None of the disclosure rules of a public company applied.

After Arthur died in 1987, a fight over his estate and over credit for the Valium-era legacy ended with his branch selling its remaining Purdue stake not long before the 1996 OxyContin launch. Mortimer and Raymond’s descendants ran the company through the years of heaviest promotion and worst harm.

Keefe rebuilds this largely from court papers because the family gave him no interviews. A clan that acts as one brand in public and as separate trusts in private can take credit together and hand out blame selectively.

In practice: Arthur’s heirs could later insist their side had nothing to do with opioids even though Arthur built the marketing template OxyContin used.

3

Safety story jumps markets

The safety reputation Purdue built with MS Contin for cancer patients was transferred, without solid evidence, to OxyContin sold for common chronic pain.

In the 1980s Purdue marketed MS Contin, a controlled-release morphine tablet, to terminal cancer patients. It argued slow release blunted the euphoric spike tied to addiction and that aggressive opioid dosing was compassion.

OxyContin, a controlled-release oxycodone tablet launched in 1996, carried the same logic into back pain, arthritis, and everyday chronic conditions. Sales materials repeated the claim that fewer than one percent of opioid patients became addicted—a figure drawn from a five-sentence 1980 journal letter that did not study long-term outpatient use.

Curtis Wright, the FDA reviewer who approved OxyContin’s original label, later left government to work for Purdue. Keefe’s point is that the danger was not a marketing accident on top of a safe drug; it was the result of moving a palliative tool into a mass market without evidence the safety claims still held.

In practice: Purdue stretched that 1980 five-sentence letter into a scientific-sounding guarantee for broad outpatient prescribing.

4

Incentives that manufacture volume

Purdue’s sales bonuses rewarded prescription volume and dose escalation, making abuse a predictable output of the pay system rather than a surprise.

Through the late 1990s Purdue expanded its sales force and tied rep bonuses directly to how much OxyContin was prescribed in each territory. Reps were pointed at doctors who already wrote high volumes of opioids, including practices later flagged as pill mills.

Speaker programs and junkets paid physicians to promote the drug to colleagues—the same circuit Arthur had used for Valium. When doctors reported abuse or early refills, field materials offered “pseudo-addiction”: drug-seeking meant undertreated pain, so the answer was a higher dose.

Internal documents produced in litigation showed leadership tracking top OxyContin prescribers and rewarding reps accordingly, with little matching effort to track overdose or diversion reports coming back from the field. Harm was the rational product of ordinary behavior under those rules.

In practice: Sales leadership ranked which doctors wrote the most OxyContin and paid representatives on that ranking while treating abuse reports as objections to manage.

5

2007 plea, family untouched

Purdue’s 2007 felony guilty plea showed a company could admit criminal misbranding of OxyContin while the owning family stayed personally clear.

Through the 2000s prescription-opioid overdose deaths rose sharply, first concentrated in rural belts such as Appalachian Virginia and Maine where OxyContin had been pushed hard to general practitioners. Western Virginia prosecutors built a misbranding case around claims the drug was less abuse-prone than other opioids.

Purdue Frederick pleaded guilty to felony misbranding and paid roughly $600 million in fines and penalties—one of the largest pharmaceutical settlements of its time. Three executives pleaded to misdemeanors, paid personal fines, and served no prison time.

No Sackler was charged or testified as a defendant. Richard Sackler, deeply involved in the launch, became president shortly afterward. The company kept selling and growing. Legal accountability stuck to the corporate shell and a few employees; the family that owned nearly all of it stayed separate. That pattern lasted more than a decade.

In practice: After the plea Richard Sackler moved into the presidency while the family faced no personal criminal charges.

6

Museums as reputation shield

For decades the Sackler name on major museum wings obscured, rather than merely decorated, the link to a company selling a dangerous opioid.

The Sackler Wing at the Metropolitan Museum housing the Temple of Dendur, the Arthur M. Sackler Museum at Harvard, the Smithsonian’s Sackler Gallery, and wings at the Louvre, the Tate, and Oxford made the name synonymous with high culture, not pills.

Gifts came from different branches across decades and were not secret, yet the public tie to Purdue stayed largely unknown outside pharma and legal circles until investigative work, including Keefe’s own 2017 Esquire piece, made it explicit. Elite institutions gained an incentive not to ask hard questions about the money; the philanthropy also predated OxyContin, letting boards treat the two as unrelated even after the link surfaced.

Reputation earned in one domain absorbed damage in another for a long time—until journalists and activists forced the dots to connect.

In practice: Keefe’s 2017 Esquire article was among the pieces that finally made the Purdue connection visible to a general audience.

7

Billions extracted first

As litigation risk rose after 2007, the family moved roughly $10.7 billion out of Purdue between 2008 and 2018, faster than claims could catch the money.

Court filings assembled in later suits showed billions distributed to Sackler members and trusts in the decade after the guilty plea, even as the epidemic’s scale became undeniable and state and local lawsuits multiplied.

Much of the money went into trusts and holding structures, some with international pieces, harder for future plaintiffs to reach than Purdue’s operating assets. The company itself kept earning huge OxyContin profits into the early 2010s, even after a 2010 reformulation meant to make pills harder to crush and snort—a change some researchers later tied to a shift toward heroin and illicit fentanyl rather than an overall drop in harm.

Keefe treats the timing as deliberate: get the fortune out before the reckoning so that whatever happened to the company, the family’s wealth was already elsewhere.

In practice: By the time bankruptcy talks began, most of the fortune litigation aimed at was no longer inside Purdue.

8

Protests outran the courts

Nan Goldin’s P.A.I.N. campaign stripped the Sackler name from major museums years before any court forced the family to surrender it.

Goldin, a photographer who became dependent on OxyContin after wrist surgery, founded Prescription Addiction Intervention Now and staged protests inside Sackler-branded museums, including a 2018 die-in at the Met’s Sackler Wing under the Temple of Dendur.

Amplified by reporting, the actions forced boards to face whether keeping the name implied endorsement of how the money was made. Through 2019 the Met, the Louvre, the Tate, and others said they would take no more Sackler gifts; some began removing the name from existing spaces.

No court order required it. Reputational pressure moved faster than civil litigation and did what more than a decade of lawsuits had not: it turned the Sackler name from asset into liability.

In practice: The 2018 Met die-in under the Temple of Dendur became the visible hinge that boards could no longer ignore.

9

Bankruptcy as family shield

Purdue’s 2019 Chapter 11 filing worked less as an insolvency remedy than as a route to permanent civil protection for Sacklers who never filed personally.

By 2019 more than two thousand lawsuits by states, cities, counties, and tribes had been consolidated. Purdue filed for bankruptcy in September 2019, proposing to reorganize as a public-benefit company whose future profits would fund addiction treatment and abatement.

The flashpoint was the demand that Sackler family members—who had not filed for personal bankruptcy and whose wealth mostly already sat outside the company—contribute several billion dollars, ultimately around six billion, in exchange for releases from civil opioid claims against them personally, delivered through the bankruptcy court without admissions of wrongdoing.

Some state attorneys general objected that bankruptcy law was being used to grant nonconsensual immunity to people who were never debtors in the case. The maneuver capped the separation built since 2007: a corporate bankruptcy, not a personal one, would buy the owners protection.

In practice: Objecting attorneys general argued the plan gave nonconsensual immunity to Sacklers who had never been debtors in the bankruptcy.

10

Felony without a person

Purdue’s 2020 criminal guilty plea convicted a corporation of felony conduct in an epidemic that killed hundreds of thousands while no individual Sackler faced a criminal charge.

In October 2020 Purdue pleaded guilty to three federal criminal charges tied to OxyContin marketing, including conspiracy to defraud the United States, and agreed to an $8.3 billion penalty—almost entirely uncollectible because the company was already in bankruptcy with limited assets left.

Separately, Sackler family members agreed to pay $225 million to resolve Justice Department civil claims, without admitting personal wrongdoing and without any individual criminal prosecution. Critics in Congress and among state attorneys general called it a symbolic conviction of an entity that cannot go to prison paired with a modest check from a family still worth billions by outside estimates.

Keefe frames this as the endpoint of the arc: Arthur’s marketing inheritance, ownership split from liability, a decade of extraction, and a bankruptcy built to formalize immunity. The system as constructed had no tool that matched the scale of harm to the scale of personal consequence for the people who had long directed the firm.

In practice: The $8.3 billion criminal penalty sat largely uncollectible inside the same bankruptcy that limited what victims could reach.